Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified

Nature Clinical Practice Nephrology

Volumn 2, Issue 6, 2006, Pages 337-339

  Ix, Joachim H ^a   Quarles, L Darryl ^b,c   Chertow, Glenn M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kidney Institute   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

End stage renal disease; Hyperparathyroidism; K DOQI guidelines; Mineral metabolism

Indexed keywords

25 HYDROXYVITAMIN D; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INFORMATION PROCESSING; KIDNEY FAILURE; MEDICAL SOCIETY; METABOLIC DISORDER; MINERAL METABOLISM; NONHUMAN; PARATHYROID HORMONE RELEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

BONE AND BONES; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; CALCIUM; EVIDENCE-BASED MEDICINE; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES; RENAL DIALYSIS; VITAMIN D DEFICIENCY;

EID: 33745950683     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0190     Document Type: Review

References (26)

1. Bricker NS et al. (1969) Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 123: 543-553
2. Dusso AS (2003) Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 85 S6-S9
3. Friedman EA (2005) Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int Suppl 95: S1-S7
4. Gotch FA et al. (2003) A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif 21: 51-57
5. Minutolo R et al. (2002) Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 13: 1046-1054
6. Delmez JA et al. (1982) Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21: 862-867
7. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3): S1-201
8. Drueke TB (2001) Control of secondary hyperparathyroidism by vitamin D derivatives. Am J Kidney Dis 37 (Suppl 2): S58-61
9. Henley C et al. (2005) 1,25-Dihydroxyvitamin D3 but not cinacalcet HCI (Sensipar®/Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20: 1370-1377
10. Mallick NP and Berlyne GM (1968) Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 2: 1316-1320
11. Shoji T et al. (2004) Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184
12. Teng M et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456
13. Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80 (Suppl): 1678S-1688S
14. Saito H et al. (2005) Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549
15. Shimada T et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435
16. Ghazali A et al. (1999) Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55: 2169-2177
17. Sadek T et al. (2003) Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18: 582-588
18. Dusso A et al. (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34: 368-375
19. Mowe M et al. (1999) Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc 47: 220-226
20. Bischoff HA et al. (1999) Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 80: 54-58
21. Dhesi JK et al. (2002) Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res 17: 891-897
22. Pfeifer M et al. (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15: 1113-1118
23. Goodman WG et al. (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483
24. Guerin AP et al. (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021
25. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252
26. Block GA et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525